Common Contracts
8 similar Letter Agreement contracts by AmpliPhi Biosciences Corp, CASI Pharmaceuticals, Inc., Cesca Therapeutics Inc., others
STRICTLY CONFIDENTIAL Innovate Biopharmaceuticals, Inc.Letter Agreement • May 1st, 2019 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Pain Therapeutics, Inc.Letter Agreement • August 20th, 2018 • Pain Therapeutics Inc • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Cesca Therapeutics Inc.Letter Agreement • March 28th, 2018 • Cesca Therapeutics Inc. • Laboratory apparatus & furniture • New York
STRICTLY CONFIDENTIALLetter Agreement • January 12th, 2018 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • New York
STRICTLY CONFIDENTIAL CASI Pharmaceuticals, Inc.Letter Agreement • October 19th, 2017 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
STRICTLY CONFIDENTIAL Kitov Pharmaceuticals Holdings Ltd.Letter Agreement • June 27th, 2016 • Kitov Pharmaceuticals Holdings Ltd. • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIALLetter Agreement • June 5th, 2015 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between Oramed Pharmaceuticals Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”) that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in conn
STRICTLY CONFIDENTIAL Spiro Rombotis President and Chief Executive Officer Cyclacel Pharmaceuticals, Inc.Letter Agreement • March 4th, 2015 • Cyclacel Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
